Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Rigel Pharmaceuticals (NQ: RIGL )

3.260 USD -0.060 (-1.81%)
Official Closing Price Updated: 5:57 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Rigel Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Rigel Announces Closing of Strategic Collaboration with Lilly
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the... 
From PR Newswire
Thinking about buying stock in Rigel Pharmaceuticals, AMC Entertainment, Vir Biotechnology, Oncolytics Biotech, or Senseonics Holdings?
InvestorsObserver issues critical PriceWatch Alerts for RIGL, AMC, VIR, ONCY, and SENS. 
From PR Newswire
Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
Topline data expected in April 2021 
From PR Newswire
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million 
From PR Newswire
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2020 financial results after market close on Tuesday, March 2, 2021. Rigel senior... 
From PR Newswire
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS. 
From PR Newswire
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications 
From PR Newswire
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
Study has the potential to facilitate a filing for Emergency Use Authorization (EUA) 
From PR Newswire
Rigel Pharmaceuticals Provides Business Update
TAVALISSE® preliminary 2020 net product sales of approximately $61.7 million, a year-over-year increase of 41% 
From PR Newswire
Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 39th Annual J.P.... 
From PR Newswire
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
Financialnewsmedia.com News Commentary 
From PR Newswire
Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American... 
From PR Newswire
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submission (NDS) for TAVALISSE® (fostamatinib disodium hexahydrate)... 
From PR Newswire
Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
FDA agrees to the proposed primary efficacy endpoint and additional secondary endpoints 
From PR Newswire
Rigel to Present at the Jefferies Virtual London Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual... 
From PR Newswire
Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
Third quarter total revenues of $18.4 million 
From PR Newswire
Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2020 financial results after market close on Thursday, November 5, 2020. Rigel senior management will... 
From PR Newswire
Thinking about buying stock in Just Energy, Extreme Networks, Aurora Cannabis, AcelRx Pharmaceuticals, or Rigel Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for JE, EXTR, ACB, ACRX, and RIGL. 
From PR Newswire
Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
Trial being conducted at NIH Clinical Center in Bethesda, Maryland and Inova Fairfax Hospital in Virginia 
From PR Newswire
Thinking about buying stock in Northern Dynasty Minerals, Checkpoint Therapeutics, Rigel Pharmaceuticals, Vaxart, or Aytu Bioscience?
InvestorsObserver issues critical PriceWatch Alerts for NAK, CKPT, RIGL, VXRT, and AYTU. 
From PR Newswire
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the... 
From PR Newswire
Rigel to Present at Two Upcoming Investor Conferences
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at two virtual investor conferences in... 
From PR Newswire
Rigel to Participate in Citi's 15th Annual BioPharma Virtual Conference
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to participate in a panel discussion on COVID-19 during... 
From PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of... 
From PR Newswire
Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program
Second quarter net product sales of $15.0 million, a year-over-year increase of 47% 
From PR Newswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2020 financial results after market close on Tuesday, August 4, 2020. Rigel senior management will... 
From PR Newswire
Rigel Announces Post-hoc Data Analysis of TAVALISSE® in Adult Patients with Immune Thrombocytopenia Published in the British Journal of Haematology
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that a paper presenting a post-hoc data analysis of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, as well as accompanying... 
From PR Newswire
Thinking about buying stock in Moleculin Biotech, VBI Vaccines, Rigel Pharmaceuticals, Delta Air Lines, or Vivint Solar?
InvestorsObserver issues critical PriceWatch Alerts for MBRX, VBIV, RIGL, DAL, and VSLR. 
From PR Newswire
Clinical Trials for Evolving Targeted Therapies Fueling Gains for Brain Tumor Therapeutics Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.